Abstract:Immunoglobulin A vasculitis (IgAV; formerly Henoch Schonlein Purpura) is the most common form of childhood vasculitis. It can occur in any age and peaks around 4–6 years old. It demonstrates seasonal variation implicating a role for environmental triggers and geographical variation. The diagnosis is made clinically and 95% of patients will present with a rash, together with any from a triad of other systems—gastrointestinal, musculoskeletal, and renal. Most cases of IgAV in children have an excellent outcome. Treatment may be required during the acute phase for gastrointestinal involvement and renal involvement, termed IgAV nephritis (previously HSP nephritis), is the most serious long-term manifestation accounting for ~1–2% of all childhood end stage kidney disease (ESKD). It therefore requires a period of renal monitoring conducted for 6–12 months. Patients presenting with nephrotic and/or nephritic syndrome or whom develop significant persistent proteinuria should undergo a renal biopsy to evaluate the extent of renal inflammation and there are now international consensus guidelines that outline the indications for when to do this. At present there is no evidence to support the use of medications at the outset in all patients to prevent subsequent renal inflammation. Consensus management guidelines suggest using oral corticosteroids for milder disease, oral, or intravenous corticosteroids plus azathioprine or mycophenolate mofetil or intravenous cyclophosphamide for moderate disease and intravenous corticosteroids with cyclophosphamide for severe disease. Angiotensin system inhibitors act as adjunctive treatment for persisting proteinuria and frequently relapsing disease may necessitate the use of immunosuppressant agents. Renal outcomes in this disease have remained static over time and progress may be hindered due to many reasons, including the lack of reliable disease biomarkers and an absence of core outcome measures allowing for accurate comparison between studies. This review article summarizes the current evidence supporting the management of this condition highlighting recent findings and areas of unmet need. In order to improve the long term outcomes in this condition international research collaboration is urgently required.

Immunoglobulin A vasculitis with periorbital edema and severe renal involvement: A case report

IgA Vasculitis:A Review on Diagnosis and Management

Venous Sinus Thrombosis in a Case of Immunoglobulin A Vasculitis and a Systemic Review of Literature

Henoch-Schönlein Purpura (IgA Vasculitis): Rapid Evidence Review

Pathogenesis of IgA Vasculitis: An Up-To-Date Review

Exploring the Diagnostic Odyssey of IgA Vasculitis

A Case Series of Unusual IgA Vasculitis

An Unusual Case of Abdominal Pain in a Geriatric Man

Childhood IgA Vasculitis (Henoch Schonlein Purpura)—Advances and Knowledge Gaps

Adult-Onset IgA Vasculitis Associated With Pulmonary-Renal Syndrome Following COVID-19 Infection: A Case Report and Literature Review

A Review of the Pathogenesis of IgA Vasculitis Nephritis in Children

Effective treatment with intravenous immunoglobulin for Henoch–Schönlein purpura with refractory gastrointestinal symptoms in an adolescent: A CARE-compliant case report

IgA vasculitis

Enterohemorrhagic Escherichia coli: trigger for small vessel vasculitis

Clinicopathological Features of Antineutrophil Cytoplasmic Antibodies Associated Vasculitis with Glomerular IgA Deposits

A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future

Posterior reversible encephalopathy syndrome in the setting of IgA vasculitis

Periorbital Edema as the Initial Manifestation of Pediatric Systemic Lupus Erythematosus

Risk Factors for Renal Involvement in Childhood Henoch-Schonlein Purpura (IgA Vasculitis)

An Immunoglobulin A Vasculitis Case Without Skin Symptoms Complicated With Severe Abdominal Symptoms

Atypical purpura and other features associated with unfavorable outcomes of IgA vasculitis (Henoch-Schönlein purpura) in children: A retrospective study